News
PASG
1.310
-2.24%
-0.030
Weekly Report: what happened at PASG last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at PASG last week (0415-0419)?
Weekly Report · 04/22 09:16
Weekly Report: what happened at PASG last week (0408-0412)?
Weekly Report · 04/15 09:15
Passage Bio, Inc.: Other definitive proxy statementsOpen document
Press release · 04/09 12:10
Weekly Report: what happened at PASG last week (0401-0405)?
Weekly Report · 04/08 09:16
Analysts’ Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
TipRanks · 04/01 11:21
Weekly Report: what happened at PASG last week (0325-0329)?
Weekly Report · 04/01 09:16
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
TipRanks · 03/26 11:20
Weekly Report: what happened at PASG last week (0318-0322)?
Weekly Report · 03/25 09:16
Passage Bio, Inc.: Statement of changes in beneficial ownership of securities
Press release · 03/19 21:22
Weekly Report: what happened at PASG last week (0311-0315)?
Weekly Report · 03/18 09:16
Weekly Report: what happened at PASG last week (0304-0308)?
Weekly Report · 03/11 09:16
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
NASDAQ · 03/07 17:00
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
Passage Bio reported earnings per share of -30 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -40 cents and above the company's expected revenue of -20 million. The stock was down 2.7% after the market closed.
Investorplace · 03/06 18:52
Passage Bio Price Target Maintained With a $14.00/Share by Canaccord Genuity
Dow Jones · 03/05 14:13
Canaccord Genuity Reiterates Buy on Passage Bio, Maintains $14 Price Target
Benzinga · 03/05 14:03
New Innovation / R&D Risk for Passage Bio, Inc. – What’s the Latest?
TipRanks · 03/05 06:01
Passage Bio files for $200M mixed shelf offering
Passage Bio files for $200M mixed shelf offering. Passage Bio, Inc. (PASG) stock down 2.7%. Company filed a prospectus related to a proposed mixed shelf offer of up to $200 million. The company is a biopharmaceutical company.
Seeking Alpha · 03/04 21:21
Passage Bio GAAP EPS of -$1.86 beats by $0.04
Seeking Alpha · 03/04 12:36
Passage Bio Welcomes Kathleen Borthwick as New CFO
TipRanks · 03/04 12:12
More
Webull provides a variety of real-time PASG stock news. You can receive the latest news about Passage Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.